ALKERMES | ALKS - Spese Di Vendita E Di Amministrazione

Prezzo Delle Azioni
33.59
Cambio Giornaliero
-0.13 -0.37%
Mensile
-3.60%
Annuale
5.68%
Q2 Previsione
32.32




Spese Di Vendita E Di Amministrazione Cambiamento Data
AbbVie USD 3.58B 316M 2026-03
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Amgen USD 1.58B 354M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.78B 425M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 151M 21M 2026-03
J&J USD 6.03B 719M 2026-03
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 2.67B 180M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Otsuka Holdings JPY 259.49B 18.81B 2026-03
Ovoca Bio EUR 632K 2.33M 2025-06
Pfizer USD 4.08B 894M 2025-12
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Vertex Pharmaceuticals USD 487M 41.9M 2025-12